Actively Recruiting
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
Led by Xuanwu Hospital, Beijing · Updated on 2025-04-27
1486
Participants Needed
1
Research Sites
142 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous thrombosis (CVT). The main question it aims to answer are: * Do cerebral veins or venous sinuses recanalize during the treatment period of edoxaban and rivaroxaban? * Do the bleeding events occur during the treatment period of edoxaban and rivaroxaban? The main tasks participants will be asked to do: * Participants will comply fully with the prescribed regimen and take the edoxaban or rivaroxaban as directed at the specified dosage. * Participants will return to hospital for scheduled follow-up assessments at months 3, 6, 9, and 12 post-enrollment to undergo face-to-face visits with investigators.
CONDITIONS
Official Title
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, any gender
- Diagnosis of cerebral venous thrombosis confirmed by MRBTI/MRV, CT/CTV, or DSA
- Acute or subacute CVT with onset to hospital visit within 4 weeks
- Treating clinician considers patient appropriate for edoxaban or rivaroxaban treatment
- Patient or legal representative able to provide written informed consent
You will not qualify if you...
- Refusal to take edoxaban or rivaroxaban for CVT treatment
- Pregnant or breastfeeding women, or women planning pregnancy during the study
- Expected need for invasive procedure before starting oral anticoagulation
- CVT caused by central nervous system infection or severe head trauma
- Active malignant tumors or within 6 months of diagnosis
- Bleeding disorders or other reasons that contraindicate anticoagulation
- Medical conditions requiring mandatory antiplatelet or anticoagulant therapy
- Use of strong CYP3A4 or P-gp inhibitors
- Severe kidney impairment (creatinine clearance less than 30 mL/min) or expected to decline
- Severe liver impairment or current acute hepatitis
- Unable to swallow medications due to consciousness or other issues
- Severe or life-threatening illness with life expectancy under 6 months
- Severe high blood pressure (systolic ≥180 mmHg or diastolic ≥110 mmHg)
- Known allergy to edoxaban or rivaroxaban
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053
Actively Recruiting
Research Team
R
Ran Meng
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here